Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens

Published: Tuesday, August 27, 2013
Last Updated: Tuesday, August 27, 2013
Bookmark and Share
One shot of the vaccine will prevent babies from five diseases at once.

The Indonesian Ministry of Health will introduce a new immunization program, and a pentavalent vaccine for babies aged 2 months to 1 year.

One shot of the pentavalent vaccine will prevent babies from five diseases at once, including Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae Type B.

The pentavalent vaccine, produced by Bio Farma, has been in development since 2007. The product will be launched along with the new immunization program by the Ministry of Health on August 22nd, in Lapangan Karang Pawitan Kabupaten Karawang.

The combination of five antigens is possible due to the similar schedule for 2, 3 & 4 month old babies. With the pentavalent vaccine, babies will require only one shot which contains the five antigens.

Babies are currently given two shots in one period of time, the DTPHB and HIB vaccines. Some babies require three shots, DPT, Hepatitis B and HIB vaccines.

The Production Director of Bio Farma, Juliman, said besides lowering the frequency of babies' shots, the pentavalent vaccine leads to greater efficiencies. "The use of pentavalent vaccine is expected to diminish production costs, cold chain costs, injector costs, and encourage health officers to be efficient. This cost efficiency will translate to affordability for the people."

Juliman added that with the various advantages, the use of pentavalent vaccine is projected to become a future trend for vaccine producers in developing countries.

Juliman spoke during the Global Alliance for Vaccines and Immunization (GAVI), held at Bio Farma on August 21st.

Clinical Trial

Bio Farma has held clinical trials for the pentavalent vaccine since 2010. The vaccine has passed the phase III clinical trial process, ensuring its efficacy for humans.

The trial was conducted with Hasan Sadikin Hospital / Medical Faculty of Padjajaran University and Cipto Mangunkusumo Hospital / Medical Faculty of Indonesian University. Pentavalent has also been registered with the National Agency of Drug & Food Control (NADFC).

"This year we will produce and supply the vaccine to four provinces, West Java, Bali, NTB and Yogyakarta, while later we will be able to produce and fulfill the demand of all provinces of Indonesia," said Juliman.

He predicted that the pentavalent vaccine demand in Indonesia will reach 15 million doses a year, based on the average number of babies' births in Indonesia of 5 million per year.

Besides fulfilling domestic demand, Bio Farma plans to export the vaccine to the other countries after the vaccine passes the WHO prequalification assessment, a requirement for the vaccine to be accepted internationally.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos